Operations Excellence: BioPharmaceutical Operations Excellence -- 2006 and Beyond

Published on: 
BioPharm International, BioPharm International-03-01-2006, Volume 19, Issue 3

. . . Popular consortium meetings have focused on successful use of tools to drive improvement in cycle time reduction, deviation reduction, and improved production efficiency.

I am pleased to introduce myself as Tefen's new contributor to this regular column. During my tenure with Tefen, I have had the opportunity to support a number of the industry's largest firms as they struggled with the challenge of changing their culture and their way of doing business. This month's column will focus on the current state of the industry, regarding operations excellence, as well as provide an update on the 2006 BioPharmaceutical Operations Excellence Consortium meetings.

Marc Puich

As the primary facilitator of the event over the past four years, I have seen a broad spectrum of presentations that highlight challenges the industry is facing within their operations. At the same time, I have witnessed some great success stories in dealing with these challenges. Where have we seen the most success within the industry over the past four years?



When initiating operations excellence programs, most companies select "Lean" concepts and tools as the primary strategy for launching the improvement process. The most popular consortium meetings have focused on the successful use of these tools to drive improvement in areas like cycle time reduction, deviation reduction, and improved production efficiency. The results from the projects are clear and measurable, and prove that even in a regulated industry, change can occur rapidly.


As a single measure, the disposition time of production lots can indicate the health of a biopharmaceutical organization. Issues in manufacturing, quality assurance, and quality control all contribute to the complexity of lot disposition. As a result, many companies place a significant focus on fixing and accelerating this process. Lot disposition time averaged 85 calendar days in the BioBenchmark study Tefen conducted in 2002. Recent reports found companies consistently achieving dispositions in 50 days or less, with low variability. Projects that drove this improvement focused primarily on accelerating the deviation management processes, the primary inhibitor of product release. Companies have more QA resources in production, performing more real time review and investigation work for problem lots. As a result, companies are more successful in meeting market needs.

Even with the success the industry has experienced over the past several years, there are still some key areas for improvement. These areas will most likely appear on the agendas of future consortium meetings, and include the topics described below.


Although progress has been made in accelerating overall lot disposition, process deviations for many companies are still a significant problem. Disposition time reduction programs have resulted in better categorization of events and faster identification of Corrective and Preventive Actions (CAPAs). However, in the interest of providing rapid review and CAPA identification, the quality of investigations has suffered. A focus for companies moving forward is how to quickly advance this process while ensuring that the true root cause has been established.


Most operations excellence programs have been initiated in production, with a manufacturing focus. When one examines the concerns of top industry executives, though, how well are these improvement programs supporting their goals? Some companies have been aggressively exploring the application of operations excellence tools, such as Design for Six Sigma in the research and development organizations. Although driving operations improvement into R&D is a dramatic cultural shift for the scientists working in and running these organizations, it is not new. Most industries have incorporated best practices from Lean and Six Sigma as a way to drive more success into the manufacturing areas. The benefits target top line growth — they drive more products through the pipeline faster, with fewer problems in manufacturing. These are good excuses for starting the process.


One of the key challenges facing production groups is the capability of the process reaching the production floor. Historically, the pressure for rapid development and product launch has resulted in development operations being less focused on "Design for Manufacturability" concepts. Once processes were transferred into the commercial line, or scaled up, operators were left with batch records that were difficult to understand and follow. The resulting deviations cause disposition delays and supply risk.

With newer information technologies such as Manufacturing Execution System, Distributed Control System, and Electronic Batch Records becoming more common, the necessary data and tools for better process understanding should improve the way companies are attacking process improvement.


The IBC Manufacturing and Distribution Summit held in Washington, D.C., in December 2005 provided a glimpse into the concerns of industry professionals. By far, the most popular session focused on the use of disposables. From an operations excellence standpoint, this makes sense — streamlining changeovers is a key initiative many companies have already pursued. And disposables can greatly reduce the load on production and quality resources, while accelerating production processes. The financial argument for adopting this in a capacity-constrained environment is abundantly clear. As we identify topics for future meetings, we will explore at how companies are using disposables to drive operational improvements.


Due to the popular support for the consortium over the past several years, Tefen is committed to conducting future events. We plan to hold an executive forum April 20–21, with the theme, "Future Plant 2015." The forum will include a visioning session, attempting to define what an operationally excellent plant will look like in the not-so-distant future, as well as the tools that will be required to get there. Participants will discuss the future of quality, R&D, manufacturing, and supply chain processes and systems. We also plan to conduct four additional meetings through the rest of the year, hopefully addressing the challenges highlighted earlier.

For additional information, please contact excellence@tefen.com or visit www.tefen.com/bio. I look forward to meeting you.

Marc Puich is a partner at Tefen Ltd. 1065 E. Hillsdale Blvd., Suite 1615, Foster City CA 94404, 650.357.1120 X117, fax 650.372.1350, marc@tefen.com